Triple therapy: worth the risk?

Minerva Med. 2018 Oct;109(5):403-405. doi: 10.23736/S0026-4806.18.05564-7.
No abstract available

Publication types

  • Meta-Analysis

MeSH terms

  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Aspirin / administration & dosage
  • Aspirin / adverse effects
  • Clopidogrel
  • Drug Synergism
  • Drug Therapy, Combination / adverse effects
  • Factor Xa Inhibitors / administration & dosage
  • Factor Xa Inhibitors / adverse effects
  • Hemorrhage / chemically induced
  • Humans
  • Mortality
  • Multicenter Studies as Topic*
  • Myocardial Infarction / etiology
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects*
  • Postoperative Complications / prevention & control
  • Purinergic P2Y Receptor Antagonists / administration & dosage
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • Randomized Controlled Trials as Topic*
  • Rivaroxaban / administration & dosage
  • Rivaroxaban / adverse effects
  • Stents
  • Stroke / prevention & control*
  • Thrombophilia / drug therapy*
  • Ticlopidine / administration & dosage
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Rivaroxaban
  • Clopidogrel
  • Ticlopidine
  • Aspirin